Sheaff Brock Investment Advisors’s Corcept Therapeutics CORT Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$951K	Buy	+8,329	New	+$507K	0.09%	173

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Sheaff Brock Investment Advisors's CORT Position: Q1 2025 in Review

Sheaff Brock Investment Advisors opened a new position in Corcept Therapeutics (CORT) in Q1 2025: 8,329 shares worth $951K. The stake represents 0.09% of the portfolio and ranks #173 among its holdings.

422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

Sheaff Brock Investment Advisors held 8,329 shares of Corcept Therapeutics worth $951K as of Q1 2025.
Corcept Therapeutics was a new Sheaff Brock Investment Advisors position in Q1 2025.
Corcept Therapeutics made up 0.09% of Sheaff Brock Investment Advisors's portfolio in Q1 2025, its #173 holding.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2025, filed 7 May 2025.